Patriage / pre-FTO intelligence
Know where to focus before you invest. Patriage brings patents, drug registers and market signals into one analyst-reviewed dossier for your generic-drug shortlist.
Pre-FTO decision brief
Molecule A
Market access & priorities for review
Focus counsel review on the UK. Resolve the German timing constraint and US evidence gap.
The deliverable
One PDF per molecule. A clear summary for your team, with the market detail and evidence your counsel needs to take the next step.
01 / The decision brief
Molecule A Three markets. Three different next steps.
Prioritise the UK for counsel review. Keep Germany under timing review. Resolve the US source gap before making an investment decision.
Take the mapped patent position to counsel for a full claim review.
Confirm the national extension before selecting a launch window.
Reconcile the missing register entry before assessing access.
Evidence before investment. Each conclusion leads to a source, a limitation and a named next action.
02 / Market access
Molecule A / market position Illustrative review windows, not launch clearance.
| Market | Review window | What drives the read | Next step |
|---|---|---|---|
| United Kingdom UK | 2028 | Compound-patent expiry Sample reference S-01 | Counsel claim review |
| Germany DE | 2030 | National extension Sample reference S-02 | Confirm extension term |
| United States US | Unresolved | Incomplete register record Sample reference S-03 | Close the evidence gap |
Scroll the table horizontally to inspect all columns
A missing record is an open question. Every date carries its basis and the follow-up needed before it can inform a decision.
03 / Evidence & actions
Molecule A / evidence register Source, limitation and next action stay together.
Example source: patent-family record and national register.
Action: Counsel confirms surviving claims and their relevance to the proposed product.
Example source: national supplementary protection certificate register.
Action: Verify the extension term and any applicable paediatric extension.
Example source: an incomplete drug-register entry.
Action: Retrieve the missing record and reconcile it with the patent estate.
This preview shows three selected sections. A full dossier also includes competitors, manufacturing complexity, litigation and safety signals, and the surviving-patents registry.
Request a full sample under NDAWhat we examine
Direct your development and legal budgets toward candidates worth a closer look. Each finding stays connected to its source.
Compound patents, national extensions and exclusivity, assessed per region and per EU member state. Every proposed date names its basis.
In your dossier Market-opening timelineApproved products and labelers across official registers, including US ANDA and NDA counts, European authorisations and UK dispensing.
In your dossier Competitor landscapeSynthetic-accessibility and chirality flags, alongside API suppliers holding an EDQM Certificate of Suitability.
In your dossier Manufacturing assessmentOpposition outcomes, litigation and safety signals, and clinical-trial status. Material findings and data gaps are surfaced for review.
In your dossier Risk & evidence registerHow it works
A managed service, with an analyst in the loop. No software to install or integration to manage.
Send your candidates and target regions. We agree the scope and put an NDA in place.
Specialist agents cross-check public sources. An analyst reviews the findings and unresolved questions.
Market timing, competitors and risks, with the sources and follow-up questions ready for your team.
AI does the research legwork. People own the decision. Patriage helps focus a formal FTO review; patent counsel provides the legal opinion.
Coverage
Every market is labelled by what its public evidence supports. Coverage is stated explicitly, and data gaps stay visible.
Sources include FDA Orange and Purple Books, EU SPC registers, Health Canada PM(NOC), EPO oppositions, EDQM CEP suppliers, PubChem and ChEMBL.
Request a quotation
Ask for a quotation for one report or a portfolio of 10 or more. Each quotation is tailored to your molecules, target markets and scope.
Evaluate a molecule your team already knows.
Prioritise a portfolio with a consistent evidence standard.
We confirm scope, pricing and delivery timing with your quotation before any work begins.
No. Patriage is a pre-FTO intelligence service that assembles evidence and focuses further review. It does not provide legal advice, replace patent counsel or substitute for the studies required to bring a generic to market.
Yes. The interactive sample above shows the format using fictional data. Request a full sample under NDA to discuss the depth and evidence with our team.
Your molecule or shortlist, target markets and any specific questions. We agree the scope and confidentiality arrangements before analysis starts. You do not need to install software.
Unresolved records and markets outside assessed coverage are labelled for verification. Each material finding is reviewed by an analyst, with its source and limitations retained in the dossier.
Evaluate Patriage
Start with one candidate and judge the evidence, the boundaries and the usefulness of the final dossier.
